Ernest Ramsay Camp, M.D., FACS

Professor and Chief, Division of Surgical Oncology

(832) 957-6500

Schedule an Appointment

Positions

Professor and Chief, Division of Surgical Oncology: Baylor College of Medicine

Olga Keith Wiess Chair of Surgery: Baylor College of Medicine

Executive Surgical Director: Dan L Duncan Comprehensive Cancer Center

Chief, Oncology Service Line: Baylor St. Luke's Medical Center

Addresses

Dan L Duncan Comprehensive Cancer Center (Clinic): O’Quinn Medical Tower at McNair
1919 Old Spanish Trail
Houston, TX, 77054
United States
Phone: (832) 957-6500
Interactive Map

Education

Fellowship at The University of Texas M.D. Anderson Cancer Center: Houston, United States; Surgical Oncology

Postdoctoral Training at The University of Texas M.D. Anderson Cancer Center: Houston, United States; T32 Research Fellowship

Residency at Shand’s Hospital, University of Florida: Gainesville

MS from Medical University of South Carolina: Charleston; Clinical Research

MD from Medical University of South Carolina: Charleston

BA from Davidson College: Davidson; Chemistry

Certifications

American Board of Surgery

Professional Interests

Surgical oncology
Pancreatic cancer
Pancreaticobiliary malignancies
Gastric cancer and other gastric malignancies
Sarcoma
Melanoma
Small bowel tumors
Neuroendocrine tumors
Gasrointestinal tumors
Minimally invasive surgery
HIPEC

Professional Statement

Dr. E. Ramsay Camp is professor and chief of the Division of Surgical Oncology in the Michael E. DeBakey Department of Surgery at Baylor College of Medicine and executive surgical director of the Dan L Duncan Comprehensive Cancer Center. He earned his undergraduate degree from Davidson College and his medical degree from the Medical University of South Carolina. He completed a general surgery residency at Shands Hospital at the University of Florida, followed by a surgical oncology fellowship at The University of Texas MD Anderson Cancer Center in 2007. Before joining Baylor as chief of surgical oncology, Dr. Camp spent 12 years on the faculty of the Medical University of South Carolina. His clinical expertise includes the surgical treatment of complex gastrointestinal tumors, including pancreatic, pancreaticobiliary, gastric, small bowel, and neuroendocrine malignancies. His clinical expertise also encompasses sarcoma, melanoma, minimally invasive surgery, and hyperthermic intraperitoneal chemotherapy (HIPEC).

Dr. Camp leads an active, externally funded research laboratory focused on the mechanisms of chemotherapy and radiation resistance in pancreatic and colorectal cancers. His research is supported by an NIH R01 and was previously supported by a VA Merit Award. He is a fellow of the American College of Surgeons and a member of the American Surgical Association, Southern Surgical Association, Society of Surgical Oncology, American Society of Clinical Oncology, American Association for Cancer Research, National Surgical Adjuvant Breast and Bowel Project (NSABP), Southwest Oncology Group (SWOG), and American College of Surgeons Oncology Group (ACOSOG).

Websites

Division of Surgical Oncology

Surgical Translational Oncology Laboratory

Clinical trial sets out to improve prognosis for pancreatic cancer patients

@CampRamsay

How robotic-assisted Whipple surgery is changing pancreatic cancer care

Laboratory for Translational Surgical Oncology

Videos

Expert cancer care at Baylor St. Luke's explained by Dr. Ernest Ramsay Camp

Selected Publications

Bowers JS, Bailey SR, Rubinstein MP, Paulos CM, and Camp ER. " Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. " Oncology Reviews. ;
Janakiraman H, Zhu Y, Becker SA, Wang C, Cross A, Curl E, Lewin D, Hoffman BJ, Warren GW, Hill EG, Timmers C, Findlay VJ, and Camp ER. " Modeling rectal cancer to advance neoadjuvant precision therapy. " International Journal of Cancer. ;
Riley JM, Cross AW, Paulos C, Rubinstein MP, Wrangle J, and Camp ER. " The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. " Cancer. ;
Zhu Y, Wang C, Becker SA, Hurst K, Nogueira LM, Findlay VJ and Camp ER. " miR-145 antagonizes SNAI1-mediated stemness and radiation resistance in colorectal cancer. " Molecular Therapeutics. ;
Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. " Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. " Cancer. ;
Skodepole A, Engelhart K, Kutlu O, Lancaster WP, Abbott A and Camp ER. " High Mitotic Rate Predicts Sentinel Lymph Node Involvement in Thin Melanomas. " J Surg Res. ;
Camp ER, and Ellis LM. " CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice. " Clinical Cancer Research. ;
Findlay VJ, Wang C, Quirk D, Hurst K, Vaena S, Watson DK, and Camp ER. " SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. " Molecular Cancer Therapeutics. ;
Esnaola NF, Chaudhary UB, O'Brien P, Garrett-Mayer E, Camp ER, Thomas M, Cole DJ, Montero AJ, Hoffman B, Romagnuolo J, and Marshall DT. " Phase II Trial of Induction Gemcitabine, Oxaliplatin, and Cetuximab followed by Selective Capecitabine-Based Chemoradiation in Patients with Nonmetastatic, Locally Advanced Pancreatic Cancer. " Int J Radiat Oncol Biol Phys. ;
Findlay VJ, Wang C, Watson DK, and Camp ER. " Epithelial -to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. " Cancer Gene Therapy. ;